Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

REYE's SYNDROME/ASPIRIN WARNING USE BY PRIVATE RETAILERS is being urged by FDA through letters mailed Aug. 23. In the letter, FDA Com. Young asks retailers of private label aspirin products to join larger aspirin mfrs. to "voluntarily amend your labels and labeling as proposed by the Aspirin Foundation for aspirin and aspirin-containing products" to warn of the possible association with Reye's Syndrome. Young requested the retailers and distributors to "remove from products packaged only for use in children (pediatric products) indication for use in 'flu' " and to add to the labels of all such products the statement: "Warning: Contact a physician before giving this medicine to children, including teenagers, with chicken pox or flu." Retailers and distributors of private label aspirin products are also requested to notify FDA of the actions they take to inform customers about Reye's Syndrome and the use of aspirin products. The commissioner requested retailers to use point-of-sale notices to advise parents and teenagers of Reye's Syndrome. Included with the letter is a copy of the American Reye's syndrome Association/Reye's Syndrome Society/National Reye's Syndrome Foundation poster for use as a point-of-sale warning of Reye's Syndrome. The poster was mailed out to pharmacists Aug. 1 and Sept. 1 and was included as a tearout in the September issue of American Druggist ("The Pink Sheet" Aug. 12, T&G-4).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts